Drug Trial Radar · NCT03650114
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,882
Actual
Start
Dec 28, 2018
Primary completion
Sep 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS). COVID-19 sub-study: The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.
Conditions
- Relapsing Multiple Sclerosis
Interventions
OfatumumabBiological
subcutaneous injection of 20 mg ofatumumab every 4 weeks
Tetanus toxoid (TT) containing vaccine (Td, Tdap)Biological
0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
13-valent pneumococcal conjugate vaccine (13-PCV)Biological
0.5mL Vial/Syringe
23-valent pneumococcal polysaccharide vaccine (23-PPV)Biological
0.5mL Vial/Syringe
Seasonal Quadrivalent influenza vaccineBiological
Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
Keyhole limpet hemocyanin (KLH) neo-antigenBiological
1mg Vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients that experience an adverse event or abnormal laboratory, vital and/or ECG results and positive suicidiality outcomesTime frame: Up to 8 years
Locations
295 sites in 37 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
North Central Neurology Associates PC
Cullman, Alabama
Barrow Neurological Clinics at St Josephs Hospital and MC
Phoenix, Arizona
Fullerton Neuro and Headache Ctr
Fullerton, California
University of California Davis
Sacramento, California
CU Anschutz Med Campus
Aurora, Colorado
Mountain Neuro Research Center PC
Basalt, Colorado
Alpine Clinical Research Center
Boulder, Colorado
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Colorado Neurological Research PC
Denver, Colorado
University of Colorado Health Neurology
Fort Collins, Colorado
Christiana Care Health Services
Newark, Delaware
Jem Research Institute
Atlantis, Florida
Neurology Offices of South Florida PLLC
Delray Beach, Florida
Infinity Clinical Research LLC
Hollywood, Florida
Homestead Assoc In Research Inc
Homestead, Florida
Neurology Associates PA
Maitland, Florida
UM Department Of Neurology
Miami, Florida
Aqualane Clinical Research
Naples, Florida
MS and Neuromuscular Center of Excellence
Oldsmar, Florida
Neurology Associates of Ormond Beach
Ormond Beach, Florida
Emerald Coast Neurology
Pensacola, Florida
Neurostudies Inc
Port Charlotte, Florida
Negroski Neurology
Sarasota, Florida
Roskamp Institute Inc
Sarasota, Florida
AMO Corporation
Tallahassee, Florida
Clinical Research of West Florida Inc
Tampa, Florida
Axiom Clinical Research of Florida
Tampa, Florida
University Of South Florida
Tampa, Florida
Premiere Research Institute
West Palm Beach, Florida
Velocity Clinical Research
Savannah, Georgia
Georgia Neurology and Sleep Medicine Assoc
Suwanee, Georgia
Hawaii Pacific Neuroscience LLC
Honolulu, Hawaii
Rush University Medical Center
Chicago, Illinois
Consultants in Neurology
Northbrook, Illinois
Josephson Wallack Munshower Neurology PC
Indianapolis, Indiana
University of Kansas Hospital
Kansas City, Kansas
College Park Family Care Center
Overland Park, Kansas
Neuro Medical Clinic of Cenla LLC
Alexandria, Louisiana
The Neuromedical Center
Baton Rouge, Louisiana
Showing 40 of 295 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.